Close

Acceleron Pharma (XLRN) Says DART Phase 2 Study of Dalantercept in RCC Didn't Met Primary Endpoint

June 12, 2017 4:31 PM EDT Send to a Friend
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login